{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:32:18Z","timestamp":1768411938678,"version":"3.49.0"},"reference-count":74,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T00:00:00Z","timestamp":1584230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of the highly selective targeted tyrosine kinase inhibitors (TKIs) has expanded the therapeutic options for chronic myeloid leukemia (CML). Patients undergoing TKI therapy should be closely monitored to ensure that the best therapeutic response and quality of life are achieved, and to control suboptimal responses and adverse events. Despite the high rate of response using current first\u2010line TKIs, treatment failure may still occur, and resistance is considered a challenge in the treatment of patients with CML. The third\u2010generation TKI, ponatinib, is a potent orally bioavailable pan BCR\u2010ABL inhibitor that inhibits both wild\u2010type and mutant <jats:italic>BCR\u2010ABL1<\/jats:italic> kinase, including the \u201cgatekeeper\u201d T315I mutation, which is resistant to all other currently available TKIs. This paper reviews the effectiveness, feasibility, and safety of ponatinib in the real\u2010life clinical management of CML. Potential prognostic factors in identifying patients most likely to benefit from ponatinib treatment will be discussed, and case presentations illustrating situations encountered in real\u2010life clinical practice are described. Ponatinib is effective in patients who have received prior TKIs in clinical studies as well as under real\u2010life conditions. Nevertheless, the risk\/benefit balance must be evaluated for each patient, particularly considering disease state, mutational status, treatment line, intolerance\/resistance to prior TKIs, age, frailty, and specific comorbidities.<\/jats:p>","DOI":"10.1111\/ejh.13408","type":"journal-article","created":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T15:19:30Z","timestamp":1583594370000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The multi\u2010tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real\u2010world data"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2255-9190","authenticated-orcid":false,"given":"Luigia","family":"Luciano","sequence":"first","affiliation":[{"name":"Hematology \u2013 Department of Clinical Medicine and Surgery Federico II University Napoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Hematology Division AORN Cardarelli Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Attolico","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Unit Policlinico of Bari Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Division of Hematology AOU Policlinico\u2010OVE Department of Surgery and Medical Specialties University of Catania Catania Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[{"name":"Hematology Division Hospital \u201cS.G. Moscati\u201d Taranto Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Malato","sequence":"additional","affiliation":[{"name":"UOC di Ematologia con UTMO Ospedali Riuniti Villa Sofia\u2010Cervello Palermo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera \u201cBianchi Melacrino Morelli\u201d Reggio Calabria Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Hematology AORN, \u201cS.G. Moscati\u201d Avellino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Hematology \u2013 Department of Clinical Medicine and Surgery Federico II University Napoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Sgherza","sequence":"additional","affiliation":[{"name":"Hematology Unit \u201cA. Perrino\u201d Hospital Brindisi Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Unit Policlinico of Bari Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.004"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.139"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.30"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0117"},{"key":"e_1_2_9_12_1","unstructured":"U. S. Federal Drug Administration (FDA).Iclusig\u00ae(Ponatinib) tablets for oral use. Prescribing Information.2012.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf. Accessed March 21 2019."},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency (EMA).Iclusig (Ponatinib). Summary of product characteristics.2013.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/iclusig\u2010article\u201020\u2010procedure\u2010product\u2010information_en.pdf. Accessed March 20 2019."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666171002142659"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719826444"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4546.4546"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.7084"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.07.007"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3063.3063"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2018.08.006"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.05.002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3337-2"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"2905","article-title":"A real life evaluation of efficacy and safety of ponatinib therapy in CML patients [Abstract]","volume":"130","author":"Luciano L","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114070"},{"key":"e_1_2_9_29_1","unstructured":"BinottoG CastagnettiF GugliottaG et al.Ponatinib 15 mg daily combining efficacy and tolerability. A retrospective survey in Italy. 23rd European Hematology Association Congress. [Abstract PS1122] 2018. Accessed March 21 2019."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.166280"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0371"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0337"},{"key":"e_1_2_9_34_1","first-page":"170","article-title":"Burden of tyrosine kinase inhibitor failure in patients with chronic myeloid leukemia","volume":"3","author":"Kropf P","year":"2014","journal-title":"J Leuk"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375535"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13966"},{"issue":"1","key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.33590\/emjoncol\/10311536","article-title":"The importance of mutational analysis in chronic myeloid leukaemia for treatment choice","volume":"4","author":"Lavallade H","year":"2016","journal-title":"EMJ Oncol"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8010"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-660977"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-666214"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30890"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197186"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.10.005"},{"issue":"1","key":"e_1_2_9_44_1","first-page":"1617","article-title":"Efficacy and safety of ponatinib in chronic phase\u2010chronic myeloid leukemia (CP\u2010CML) according to the extent of treatment with prior tyrosine kinase inhibitors (TKIs): final (5\u2010year) results of the PACE Study. [Abstract]","volume":"130","author":"Hochhaus A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2820-x"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25648"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1498.1498"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2738.2738"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0623-7"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3258-0"},{"issue":"4","key":"e_1_2_9_52_1","first-page":"261","article-title":"Geriatric assessment for oncologists","volume":"12","author":"Korc\u2010Grodzicki B","year":"2015","journal-title":"Cancer Biol Med"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.037"},{"issue":"5","key":"e_1_2_9_56_1","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11629"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu490"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.07.005"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2402-x"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294330"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11657"},{"key":"e_1_2_9_64_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia 2012\u20132018.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf."},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.008"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3144-1"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00114-3"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2606"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140686"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.10.002"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1480719"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.326"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1366852"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T18:28:23Z","timestamp":1693765703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/ejh.13408"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13408","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]},"assertion":[{"value":"2019-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}